PPI use associated with more severe illness from COVID-19

A Korean cohort study did not find any association between use of proton-pump inhibitors (PPIs) and risk of infection with SARS-CoV-2, but current use was associated with higher risk of a composite endpoint that included ICU admission, mechanical ventilation, or death from COVID-19.

Read the full article here

Related Articles

Spotlight on MASLD

Recent studies offered recommendations and evidence on screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis, as well as using medications to reduce the…